• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

    1.790 -0.010 (-0.56%)
    Streaming Delayed Price Updated: 9:40 AM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,722
    Open 1.810
    Bid (Size) 1.790 (100)
    Ask (Size) 1.810 (300)
    Prev. Close 1.800
    Today's Range 1.790 - 1.840
    52wk Range 1.500 - 43.65
    Shares Outstanding 1,524,535
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    On Thursday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill

    Performance

    YTD
    -56.1%
    -56.1%
    1 Month
    -11.4%
    -11.4%
    3 Month
    -44.4%
    -44.4%
    6 Month
    -54.8%
    -54.8%
    1 Year
    -93.9%
    -93.9%

    More News

    Read More
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    DarkHorse Begins to Take Shape: Sphere 3D (NASDAQ: ANY) Marks a Key Milestone in AI Infrastructure Leadership
    Via AB Newswire
    Topics Artificial Intelligence
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    Top stock movements in today's session. ↗
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
    Via Chartmill
    News headline image
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    News headline image
    TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire

    Frequently Asked Questions

    Is Tvardi Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Tvardi Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Tvardi Therapeutics, Inc. - Common Stock trade on?
    Tvardi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tvardi Therapeutics, Inc. - Common Stock?
    The ticker symbol for Tvardi Therapeutics, Inc. - Common Stock is TVRD on the Nasdaq Stock Market
    What is the current price of Tvardi Therapeutics, Inc. - Common Stock?
    The current price of Tvardi Therapeutics, Inc. - Common Stock is 1.790
    When was Tvardi Therapeutics, Inc. - Common Stock last traded?
    The last trade of Tvardi Therapeutics, Inc. - Common Stock was at 09/01/26 09:40 AM ET
    What is the market capitalization of Tvardi Therapeutics, Inc. - Common Stock?
    The market capitalization of Tvardi Therapeutics, Inc. - Common Stock is 2.73M
    How many shares of Tvardi Therapeutics, Inc. - Common Stock are outstanding?
    Tvardi Therapeutics, Inc. - Common Stock has 3M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.